A restructured ASX micro-cap biotech betting on first-in-class pan-LOX inhibition—five 2026 readouts could unlock a major re-rating, but the path is highly binary and partner-dependent.
Overview
Syntara Limited (SNT.AX), formerly Pharmaxis, is an Australian clinical-stage biotech that executed a transformative pivot in late 2023 by divesting its respiratory commercial/manufacturing unit and refocusing exclusively on high-value drug development. The company is positioned as a global specialist in amine oxidase chemistry, targeting enzymes (notably LOX and SSAO/MAO-B) that regulate extracellular matrix structure; dysregulation is implicated in high-unmet-need diseases such as myelofibrosis (MF), myelodysplastic syndrome (MDS), fibrotic skin scarring (keloids/hypertrophic scars), and neurodegeneration (Parkinson’s pathway via iRBD). Post-divestment, Syntara materially reduced operational complexity and cut core annual expenses by >60% (~A$14M), shifting to a model where cash inflows are primarily non-operational: an eight-year residual royalty stream from the sold mannitol products, non-dilutive grants, and the Australian R&D tax incentive. The pipeline is led by SNT-5505 (amsulostat), a pan-LOX inhibitor in MF/MDS targeting an addressable market cited as >US$4.5B, with early signals including favorable safety and a reported 62% TSS50 symptom reduction through 38 weeks. With proforma cash of ~A$12.3M (Dec 2025) and an optimized burn intended to support a catalyst-heavy 2026, Syntara is framed as a focused, capital-efficient fibrosis-modulation play where near-term value hinges on multiple clinical readouts and potential partnering.